Latest filings (excl ownership)
8-K
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
16 Apr 24
8-K
Other Events
11 Apr 24
8-K
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
9 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
BrainStorm Issues 2023 Letter to Shareholders
20 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Nov 23
8-K
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
DEF 14A
Definitive proxy
8 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 23
8-K
BrainStorm Cell Therapeutics Announces Strategic Realignment
24 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
19 Jul 23
424B5
Prospectus supplement for primary offering
19 Jul 23
8-K
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
20 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
8-K
Departure of Directors or Certain Officers
24 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
30 Mar 23
8-K
Regulation FD Disclosure
27 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
11 Jan 23
8-K
BrainStorm Cell Therapeutics Announces Promotion of
4 Jan 23
DEF 14A
Definitive proxy
13 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
14 Nov 22
8-K
BrainStorm Presents New Biomarker Analyses from NurOwn’s Phase 3 ALS Trial at the ALS ONE Research Symposium
11 Oct 22
8-K
Entry into a Material Definitive Agreement
22 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
8-K
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
16 May 22
10-K
2021 FY
Annual report
28 Mar 22
Latest ownership filings
4
Chaim Lebovits
25 Apr 24
3
Ibrahim B. Dagher
22 Apr 24
4
Chaim Lebovits
19 Apr 24
4
Stacy Lindborg
13 Mar 24
4
Uri Yablonka
13 Mar 24
4
Alla Patlis
13 Mar 24
4
Chaim Lebovits
13 Mar 24
SC 13G/A
Ness Kevin Dean
12 Feb 24
4
Stacy Lindborg
5 Sep 23
4
Stacy Lindborg
7 Aug 23
4
Chaim Lebovits
4 Aug 23
4
Nir Naor
21 Jun 23
3
Nir Naor
21 Jun 23
4
Kirk Taylor
1 May 23
3
Kirk Taylor
1 May 23
4
Chaim Lebovits
24 Apr 23
4
Stacy Lindborg
24 Apr 23
SC 13G/A
Ness Kevin Dean
5 Apr 23
4
Stacy Lindborg
4 Jan 23
4
Chaim Lebovits
4 Jan 23
4
JACOB A FRENKEL
8 Apr 22
4
Ralph Dr. Kern
14 Mar 22
SC 13G
Abbhi Investments, LLC
14 Feb 22
SC 13G
Ness Kevin Dean
4 Feb 22
4
Anthony J. Polverino
3 Feb 22
4
MALCOLM S TAUB
17 Dec 21
4
Anthony J. Polverino
17 Dec 21
4
June Sherie Almenoff
17 Dec 21
4
Uri Yablonka
17 Dec 21
4
IRIT ARBEL
17 Dec 21
4
Ralph Dr. Kern
10 Dec 21
4
Chaim Lebovits
10 Dec 21
4
MALCOLM S TAUB
10 Dec 21
4
Anthony J. Polverino
10 Dec 21
4
IRIT ARBEL
10 Dec 21
4
JACOB A FRENKEL
10 Dec 21
4
Sankesh Abbhi
10 Dec 21
4
Uri Yablonka
10 Dec 21
4
June Sherie Almenoff
10 Dec 21
3
Menghisteab Bairu
4 Nov 21